Trial Profile

A Multicenter Phase 3 Study Comparing the Diagnostic Accuracy of 99mTc EC DG SPECT/CT Versus 18F FDG PET/CT for Diagnosing and Staging Patients Who Have Clinical and Radiological (CT) Evidence Consistent With a Diagnosis of Lung Cancer

Status: Not yet recruiting

Phase of Trial: Phase III

Latest Information Update: 08 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tc 99m ethylenedicysteine deoxyglucose (Primary) ; Fludeoxyglucose F-18
Indications Lung cancer
Focus Diagnostic use
Sponsors CellPoint

03 Apr 2025 Planned End Date changed from 1 Mar 2023 to 1 Dec 2026.
03 Apr 2025 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2025.
03 Apr 2025 Planned initiation date changed to 1 May 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com